Antiangiogenic gene therapy - Applications of soluble FLT-1 receptor;Antyangiogenna terapia genowa - Próby wykorzystania rozpuszczalnej formy receptora FLT-1

Advances in Clinical and Experimental Medicine

Volumn 13, Issue 2, 2004, Pages 227-233

  Małecki, Maciej ^a   Jastrzebski, Zenon ^b   Przybyszewska, Małgorzata ^a   Proczka, Robert ^c   Janik, Przemysław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Narodowego Instytutu Zdrowia Publicz ^*  (Poland)

^c AM   (Poland)

Author keywords

Angiogenesis; Cancer; Gene therapy

Indexed keywords

COMPLEMENTARY DNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL OBSERVATION; CONTROLLED STUDY; CULTURE MEDIUM; EXPERIMENTAL NEOPLASM; EXPRESSION VECTOR; GENE CONSTRUCT; GENE THERAPY; GENETIC CODE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PERITONEAL FLUID; PROTEIN SECRETION; SOLID TUMOR; SURVIVAL TIME;

ANIMALIA; VECTORS;

EID: 2542487578     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Feldman AL, Libutti SK: Progress in antiangiogenic gene therapy of cancer. Cancer 2000, 89, 1181-1194.
2. Wilczyńska U, Szary J, Szala S: Antyangiogenna terapia genowa. Współczesna Onkologia 1999, 4, 139-142.
3. Szala S, Szary J, Cichoń T, Sochanik A: Antiangiogenic gene therapy in inhibition of metastasis. Acta Biochim Pol 2002, 49, 313-321.
4. Zhang H-T, Harris AL: Anti-angiogenic therapies in cancer clinical trials. Exp Opin Invest Drugs 1998, 7, 1629-1655.
5. Ferrara N, Gerber H-P, LeCouter J: The biology of VEGF and its receptors. Nat Genet 2003, 9, 669-676.
6. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clinic Oncol 2002, 20, 3906-3927.
7. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993, 90, 10705-10709.
8. Hornig CH, Weich HA: Soluble VEGF receptors. Angiogenesis 1999, 3, 33-39.
9. Hornig CH, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA: Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000, 80, 443-454.
10. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA: Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998, 241, 161-170.
11. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998, 95, 8795-8800.
12. Bainbridge JW, Mistry A, de Alwis M, Paleolog E, Baker A, Thrasher AJ, Ali RR: Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002, 9, 320-326.
13. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, Yang HS, Lai H, Kovesdi I, Carrion M, Wei L, Campochiaro PA: Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barier. Hum Gene Ther 2003, 14, 129-141.
14. Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE: Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002, 9, 804-813.
15. Jastrzebski Z, Małecki M, Janik P: Badanie stopnia oczyszczenia z endotoksyn bakteryjnych preparatów plazmidowych przygotowanych dla potrzeb angiogennej terapii genowej. Farmacja Polska 2003, 59, 171-175.
16. Sidky YA, Auerbach R: Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs-host reaction. J Exp Med 1975, 141, 1084-1100.
17. Małecki M, Przybyszewska M, Janik P: In vitro and in vivo study of the expression vector encoding vascular endothelial growth factor. Arch Immun Ther Exp 2001, 49, 243-246.
18. Szary J, Kalita K, Przybyszewska M, Dus D, Kieda C, Janik P, Szala S: KDR promoter can transcriptionally target cytosine deaminase suicide gene to cancer cells of nonendothelial origin. Anticancer Res 2001, 21, 3471-3475.
19. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, Curiel DT: Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001, 7, 2057-2066.
20. Hasumi Y, Mizukami H, Urabe M, Kohnor T, Takeuchi K, Kume A, Momoeda M, Yoshikawa H, Tsuruo T, Shibuya M, Taketani Y, Ozawa K: Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002, 62, 2019-2023
21. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Nat Cancer Instit 1995, 87, 506-516.
22. Mori A, Arii S, Furutani M, Mizumoto M, Uchida S, Furuyama H, Kondo Y, Gorriu-Rivas MJ, Furumoto K, Kaneda Y, Imamura M: Soluble Flt-1 gene therapy for peritoteal metastases using HVJ-cationic liposomes. Gene Ther. 2000, 7, 1027-1033.
23. Yang W, Arii S, Mori A, Furumoto K, Nakao T, Isobe N, Murata T, Onodera H, Imamura M: sFlt-1 gene transfected fibroblsts: a wound-specific gene therapy inhibits local cancer recurrence. Cancer Res 2001, 61, 7840-7845.
24. Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S: Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2002, 25, 111-121.
25. Takayama K, Ueno H, Nakanishi Y, Sakamato T, Inoue K, Shimizu K, Oohashi H, Hara N: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000, 60, 2169-2177.
26. Budryk M, Cichoń T, Szala S: Direct in vivo transfer of plasmid DNA into murine tumors: Effects of endotoxin presence and transgene localization. Acta Biochim Pol 2001, 48, 795-800.